Multifunctional reagent for the synthesis of thiol modified oligomers

ABSTRACT

The invention relates to compounds of formula (I), wherein Z represents a hydrocarbon with 2 to 28 C atoms, wherein Z can also comprise elements N, O, P, S, Si and halogen as heteroatoms, R 1  and R 2  are identical or different sulfur protecting groups, wherein both S atoms can also form a disulfide bridge and in said case R 1  and R 2  are not present; protecting group Y 1  represents protecting group NH, protecting group NR 4 , protecting group O. CONH protecting group, protecting group OOC, protecting group S—S, —CH(protecting group O) 2  or —CR 5 (protecting group O) 2  or protecting group S; Y 2  represents —OH, —NH 2 , —NHR 3 , —NR 3 R 4 , —COOH, —COCl, —COOCO—R 6 , —CONH 2 , —CONHR 3 , —COOR 3 , —SO 3 H, —SO 3C I, —SH, —S—SR 3 , —CHO, —COR 3 , —C 2 H 3 O, halogen, —N 3 , —NH—NH 2 , —NCO, —NCS, wherein R 3  represents alkyl, heteroalkyl, aryl, cycloalkyl or a protecting group, wherein R 3  can be identical or different in groups Y 1  and Y 2 , R 4  is s protecting group, wherein R 4  can be identical or different in groups Y 1  and Y 2 , and wherein R 4  and R 3  can be identical or different, R 5  represents alkyl, aryl or cycloalkyl, wherein R 5  can be in groups Y 1  and Y 2  and R 6  represents alkyl, heteroalkyl, aryl or cycloalkyl, wherein R 6  can be identical or different in groups Y 1  and Y 2 , wherein Y 2  can also represent a group of formula (II) or formula (III), wherein X 1  represents halogen or a substituted amine, X 2  represents an alkyl, alkoxy, aryloxy radical or a cyano derivative of an alkyl, alkoxy, aryloxy radical, X 3  represents halogen, an amino function or oxygen and X 4  represents an alkyl, alkoxy, aryloxy radical or X 4  equals H if X 3 =oxygen.

TECHNICAL FIELD

This invention concerns a multifunctional reagent for the synthesis of thiol modified oligomers.

STATE OF THE ART

Nucleic acids can be synthesized chemically or enzymatically. Depending on the Nucleotide building block used and the reaction step for coupling it to the next nucleotide in the sequence, different procedures can be distinguished: The phosphodiester method, the phosphotriester method and phosphoramidite method (Gait, M. J. et al., Oligonucleotide Synthesis: A Practical Approach, IRL Press Oxford, 1984; Protocols for Oligonucleotides and Analogs, Agrawal, S., Humana Press, New Jersey, 1993). The phosphoramidite method does not use derivatives of phosphoric acid, instead it uses derivatives of phosphorous acid, so called phosphoramidites.

The phosphoramidite method can be adapted to a solid phase method, where the growing nucleotide sequence is bound at a polymer carrier. This method considerably simplifies the separation of the excess synthesis reagents and building blocks as well as the purification of the oligonucleotide sequence. Commercially available synthesizers operate according to this principle.

Nucleic acids with known nucleotide sequences have a particular application in the specific detection of DNA in biological samples. In such tests the property of single nucleotide sequences are used, namely that they can form a double strand with their complimentary strand. The process of forming a double strand is called hybridization (Nucleic Acids in Chemistry and Biology, Blackburn, M. G. and Gait, J. M., Oxford University Press).

The formation of a double strand can be detected, if a modified single stranded complimentary nucleic acid is given for hybridisation to the single strand nucleic acid or the single stranded nucleic acid itself has a modification. Modifications can be i.e. fluorophores, radioisotopes or electro labels.

The application of marked targets for the detection of hybridization events has certain disadvantages. In the first place, the marking has to be done before the actual measurement. This requires an additional synthesis step and additional working time. Furthermore it is difficult to ensure a homogenous marking of the samples. Also, stringent washing is necessary to remove non bound or unspecific bound samples after hybridization.

Oligonucleotides and polymers in general can be immobilized on surfaces by well known methods i.e. by non covalent adsorption or by covalent couplings onto a surface (WO 00/42217; U.S. Pat. No. 6,312,906). Especially attractive procedures to immobilize oligonucleotides onto a SiO₂ surface (glass) are based on well established silicon chemistry (Parkam et al., Biochem. Biophys. Res. Commun., 1 :1-6, 1978; Lund et al., Nucl. Acids Res. 16 :10861-10880, 1988). For example epoxide modified SiO₂ surfaces can be coated by aminofunctionalized oligonucleotides.

The chemisorption on gold was investigated more closely from 1983. Nuzzo and Allara (J. Am. Chem. Soc. 105, 4481, 1983) discovered that thiol and disulfides adsorb on gold in ordered monolayers. The resulting covalent bond between gold and sulfur has a binding energy of 30-40 kcal/mol. Bain et al. (J. Am. Chem. Soc. 111, 321, 1989; J. Am. Chem. Soc. 111, 7155, 1989) described the property of the bonding between organo sulfur compounds and gold. The strong coordinative gold sulfur bonding advances the spontaneous accumulation of monolayers. Bain et al. argue that the formation of those monolayers are influenced by several factors (i.e. temperature, solvent, concentration and chainlength of the adsorbent and concentration of salt). The adsorption is comprised of two steps: The formation of a first monolayer coating about 80-90% of the surface is achieved within minutes, and the coating of the remaining area which requires a process lasting several hours. Displacements on the surface (i.e. solvent) and lateral diffusion probably play a role in that process. These experiments provide the foundation for the attachment of thiolmodified oligonucleotides.

Oligonucleotides attached onto the surface by one thiol bond, simply expressed by the term “Au—S-Oligonucleotide”, are unstable under mechanical stress (i. e. washing steps). The stability of the oligonucleotide on the surface is increased by multiple formed Au—S-Bondings. A very stable attachment of the oligonucleotides brings enormous advantages for DNA Chip technology.

A variant for the attachment of DNA onto gold or platinum surfaces is provided by the developed process of Whitesides and co-workers (Lee et al., Pure & Appl. Chem. 63, 821, 1991) to generate thiol monolayers on gold surfaces. The free thiol group of a dithiol precoated metal surface (i.e. 1.10-Decandithiol) reacts with a bromacetyl modified oligonucleotide.

Sulfur containing phophoramidites or polymer carriers can be used for the production of thiol modified oligonucleotides. Examples of compounds for the coupling of disulfid units are the phosporamidite DMT-O—(CH₂)₆—S—S—(CH₂)₆—O—P(OCE)(NiPr₂) or compounds of the general formula R1-S—S—R²—O—P(OCE)(NiPr₂) (see EP 523 978). Another possibility to couple a thiol anchor to an oligonucleotide is the use of the phosphoramidite MMT-S—(CH₂)₆—O—P(OCE)(NiPr₂), however this has the disadvantage of the elaborate cleavage of the MMT group by AgNO₃.

In addition there are two further thiol carriers with C-3 and C-6 spacers for oligonucleotide synthesis (Glen Research).

In spite of the above described state of the art there is still a need for multifunctional thiol containing monomers able to form a polyfunctional thiol anchor, through which a stable attachment of molecules or polymers onto surfaces will be made possible.

DISCLOSURE OF THE INVENTION

The task of the present invention is to make thiol containing monomers available for the preparation of polyfunctional thiol compounds.

According to the invention the task is fulfilled by the compounds as stated in independent claim 1. Further attractive details, aspects and developments of the present invention follow from the dependent claims, the description, the figures and the examples.

In this presented invention the following abbreviations and terms will be used:

-   A: Adenine -   ACN: Acetonitrile -   Base: A, G, T, C or U -   C: Cytosine -   DMT: 4,4′-Dimethoxytrityl -   DNA: Desoxyribonucleic Acid -   E^(˜): Alternating Voltage -   EI: Electrospray Ionisation -   EtOAc: Ethylacetate -   Et₃N: Triethylamine -   f: Alternating Voltage Frequency -   Fmoc: 9-Fluorenylmethoxycarbonyl -   G: Guanine -   HPLC: Hoch Pressure Liquid Chromatography -   iPr: Isopropyl -   NMR: Nucleic Magnetic Resonance -   M: Mass -   MsCl: Mesylchloride or Methansulfonylchloride -   MeOH: Methanol -   MS: Mass Spectrometry -   mV: Millivolt -   C_(q): Quarternary Carbon -   C_(arom): Aromatic Carbon -   H_(arom): Aromatic Hydrogen -   OD₂₆₀: Optical Density (260 nm) -   OCE: Cyanoethoxy -   Oligomer: Equivalent to Nucleic Acid Oligomer -   Oligonucleotide: DNA-, PNA- or RNA-Fragment with no specified     chainlength of bases -   PNA: Peptide Nucleic Acid (—NH—(CH₂)₂—N(COCH₂-Base)-CH₂CO; synthetic     DNA or RNA in which the sugar phosphate unit is substituted by an     amino acid. PNA can be hybridized with DNA or RNA). -   RNA: Ribonucleic Acid -   R_(f): Retention at TLC relative to the solvent front -   rms: root mean square -   RP: Reverse Phase -   s: Singlet -   SPR: Surface Resonance Spectroscopy -   T: Thymine -   TCL: Thin Liquid Chromatography -   U: Uracile -   v: velocity of feed

Every formula is to be interpreted in a way such that the corresponding chiral enantiomers are included.

The presented invention includes compounds of the formula (I)

Where Z is a hydrocarbon of 2 to 28 C atoms, where Z can also include heteroatoms of the elements N, O, P, S, Si and halogen, R¹ and R² are the same or different H or sulfur protecting groups, where both S atoms could also form a disulfide bridge and in which case R^(1,) R² would not exist, protecting-group-Y¹, is protecting-group-NH, protecting-group-NR⁴, protecting-group-O, CONH-protecting-group, protecting-group-OOC, protecting-group-S—S, —CH(protecting-group-O)₂, or —CR⁵(protecting-groupO)₂ or protecting-group-S, Y² is —OH, —NH₂, —NHR³, —NR³R⁴, —COOH, —COCl, —COOCO—R⁶, —CONH₂, —CONHR³, —COOR³, —SO₃H, —SO₃Cl, —SH, —S—SR³, —CHO, —COR³, —C₂H₃O, halogen, —N₃, —NH—NH₂, —NCO, —NCS, where R³ is alkyl, heteroalkyl, aryl, cycloalkyl or a protecting group, where R³ can be the same or different in the groups Y¹ and Y², R⁴ is a protecting group, where R⁴ can be the same or different in the groups Y¹ and Y², and where R⁴ and R³ can be the same or different, R⁵ is alkyl, aryl, cycloalkyl, where R⁵ can be the same or different in the groups Y¹ and Y² and R⁵ is alkyl, heteroalkyl, aryl, or cycloalkyl, where R⁶ can be the same or different in the groups Y¹ and Y², where Y² can also be a group of the formula (II) or (III),

Where X¹ is a halogen or a substituted amine, X² is alkyl, alkoxy, aryloxy or a cyano derivative of alkyl, alkoxy, aryloxy, X³ is a halogen, an amino group or oxygen and X⁴ is alkyl, alkoxy, aryloxy or X⁴ is H where X³ is oxygen.

The invented compounds are substances consisting of at least four functional groups, of which two are thiols (R¹ , R²═H), thioethers or disulfides, where both sulfur atoms can be joined together to form a disulfide bridge and R¹, R² do not exist. Y¹ is a functional group with a protecting group. Y² is a functional group, which serves amongst other things for the activation of the invented compounds for chemical reactions. Such chemical reactions are for example a polymerisation or an attachment to a polymeric carrier material. Where Y² can be an already activated functional group or a to be activated functional group. The fundamental body Z is a structure of hydrocarbon consisting of 2 to 28 atoms, where Z can also include heteroatoms of the elements N, O, P, S, Si and halogen. The compounds of formula (I) have at least one protecting group.

The invented compounds can be used for the directed and defined construction of oligomers, or polymers with an exactly defined number of sulfur atoms. For which the selective cleavage of a protecting group is a necessary prerequisite. The chemical reaction of the monomers must not influence the integrity of the protecting group. The existing R¹, R² at the sulfur must be chemically stable during polymerisation which includes the activation of the functional group and the cleavage of the protecting group: This means the protecting group at Y¹, has to be orthogonally or selectively cleavable to R¹, R² at the sulfur.

Should R¹ and R² not exist and as a result the two sulfur atoms are joined together to form a disulfide bridge, the fact that the disulfide unit is not located in the backbone of the polymer represents a special advantage in that a cleavage of the disulfide bridge/s does not cause a destruction of the polymer.

Protecting groups can be amongst others triphenylmethyl-, t-butoxycarbonyl-, benzyl-, 2,4dinitrophenyl-, 9-fluorenylmethoxycarbonyl-, allyloxycarbonyl-, benzyloxymethyl-, acetyl-, 4azidobenzyloxycarbonyl-, acetamidomethyl-, 1-adamantyl-, 1-adamantyloxycarbonyl-, anisyl, benzamidomethyl-, biphenyldimethylsilyl-, 2,4dimethylthiophenoxycarbonyl-, 1-methyl-1-(4-biphenyl)ethoxycarbonyl-, benzothiazole-2-sulfonyl-, t-butoxymethyl-, benzoyl-, benzyloxycarbonyl-, cyclohexan-1,2-diacetal-, cyclohexyl-, 2-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl-, 1-methyl-1-(3,5-dimethoxyphenyl)ethoxycarbonyl-, diethylisopropylsilyl-, 1,3-dithianyl-2-methyl-, 2,4dimethoxybenzyl-, dithianylmethoxycarbonyl-, dimethoxytrityl-, p,p′-dinitrobenzhydryl-, 2,4-dinitrophenyl-, 2,4dimethylpent-3-yloxycarbonyl-, 2-(diphenylphosphino)ethyl-, 9-fluorenylmethyl-, levulinoyl-, p-methoxybenzensulfonyl-, 2,6-dimethoxy-4-methoxybenzensulfonyl-, monomethoxytrityl-, methoxyphenylsulfonyl-, mesitylensulfonyl-, o-nitrobenzyl-, 2-[2-(benzyloxy)ethyl]benzoyl-, 3-(3-pyridyl)allyloxycarbonyl-, 2,2,5,7,8-pentamethylchroman-6-sulfonyl-, pivaloyloxymethyl-, t-butyidimethylsilyl-, t-butyldiphenylsilyl-, 2,2,2-trichloro-1,1-dimethylethyl-, trifluoroacetyl-, triisobutylsilyl-, 2,4,6-trimethylbenzyl-, trimethoxybenzyl-, p-toluensulfonyl- or benzyloxycarbonyl-. Further protecting groups can be found in Greene, T. W., Protective Groups in Organic Synthesis, Wiley-Interscience, 1999.

R¹ and R² are identical or disparate sulfur protecting groups, which can be amongst others derivatives of benzyl, triphenylmethyl, substituted methyl, benzoyl-, trifluoracetyl- or t-butoxycarbonyl-groups. In addition the thiols can be protected as disulfides i.e. S-ethylsulfides, S-phenyldisulfides or as thiocarbamates. Further protecting groups can be found in Greene, T. W., Protective Groups in Organic Synthesis, Wiley-Interscience, 1999.

All of the invented compounds can be incorporated in oligomers as monomer units.

The invented compounds can be singly or multiply attached, independently of the position in the nucleotide oligomers, peptide oligomers or other molecules. Therefore for example the attachment of any molecule and also polymers onto a surface or at a polymer carrier using a polythiol anchor is possible. By the activation of the polyfunctional thiol anchor multiple attachments of the molecule onto the surface (i.e. gold surface) or to another polymer carder are formed. For this special preactivated surfaces (i.e. surfaces activated by aldehyde or maleimide) or special polymer compounds having thiol reactive groups for example peptides, proteins, PNA, RNA, LNA (locked nucleic acids) can be used. Those invented compounds that are attached at molecules or in particular at polymers can also be used for the attachment of markers (labels) or other functionalities at molecules or in particular at polymers.

An advantage of the invented compounds is the possibility to incorporate multiple SH groups into oligomers thereby generating higher stability through the immobilization of the oligomers onto a surface. Further advantage is the possibility to couple various molecules i. e. polymers, peptides, proteins or oligonucleotides at a polymer with multiple SH-groups.

Y² can also be coupled direct or via a linker to a solid carrier material i.e. CPG (controlled pore glass), microbeads, polymers (i.e. polystyrene) or membranes. To synthesize nucleic acids, the invented compounds will normally be attached to an solid carrier via an aminoalkyl (LCM=long chain alkyl amine).

The preferred in the context of the presented invention reactive phosphor intermediates can be singly or multiply incorporated at the 3′ end, in the middle and at the 5′ end of an oligonucleotide. By activation a multiple polyfunctional thiol anchor can be liberated, which can be used for a multiple attachment for example of an oligonucleotide onto a surface; onto preactivated surfaces (i.e. aldehyde, maleimide), or at other polymer compounds (i.e. proteins, PNA, RNA, LNA) having groups reactive to thiols. Furthermore this polyfunctional polythiol anchor can be used for the directed multiple attachment of markers and ligands to molecules or polymers. Markers and ligands may be for example ezymatic, chromogene, fluorogene, radioactive, chemiluminiscent labels, in nucleic acids oligomers intercalating agents, metals, metal ions, drugs, hormones, proteins, peptides, nucleolytic or proteolytic agents, especially binding agents (like i.e. biotin, antigenes, haptenes, antibodies, receptors) and other compounds of biological interest, which i.e. influence the transport through biological membranes or change the solubility of oligonucleotides. There are known procedures, which make it possible to couple these ligands and markers to thiol groups such as for example by maleimides. aldehydes and halogenacetyl compounds (Means, G. M. and R. E. Feeney, Chemical Modification of Proteins, Holden-Day Inc., 1971; Feeney, R. E., Int. J. Peptide Protein Res., 29: 145-161, 1987; Eritja, R. et al., Tetrahedron, 47, 4113-4120, 1991).

The bonding between the surface and the oligonucleotide via one thiol anchor, simplified as surface-S-oligonucleotide, is not stable to mechanical stress, for example during washing steps. One of the advantages of the presented invention is the possibility to couple a poly anchor at an oligonucleotide, such that the attachment of the oligonucleotide to gold is optimised by several Au—S-bondings. In which case the conditions for the attachment onto the surface for example the concentration of salt used, the applied potential at the surface or the kind of premodificated surface are crucial. Furthermore thiols already deposited on the surface can be displaced by this poly anchor.

Furthermore the deprotection of the sulfur protecting group by AgNO3 is avoided by the use of DMT as the protecting group. The DMT protecting group can be cleaved by mild acid treatment, which is compatible with oligonucleotide chemistry. The presented invented compounds can be used under the usual standard conditions for oligonucleotide chemistry.

The phosphorous containing compounds include intermediates that can be used in the H-phosphonate, phosphotriester, phosphorchloridite and phosphoramidite methods of oligonucleotide synthesis. Furthermore these intermediates can include phosphodiester analogs such as methyl phosphonates, methyl phosphates, phosphorthioates and phosphoramidites (EP 0 523 978), for modifications at 5′-, 3′ end and/or in the sequence.

According to a preferred embodiment of the invention Y² is equivalent to formula II or III, in which X¹ is a halogen and X²is methyl or R⁷O—, where R⁷ is alkyl, cycloalkyl, aryl or a cyano derivative of alkyl, aryl, or X² is equivalent to R⁷O— and X¹ is equivalent to —NR⁸R⁹, where R⁸ and R⁹ are independently from each other alkyl, heteroalkyl, cycloalkyl, aryl or R⁸ and R⁹ are joined together to form with the N atom a cyclic structure of 4 to 7 C atoms, in which one C atom of the cyclic structure can be replaced by O or S, or X³═O— and X⁴═H or is R¹⁰O—, in which R¹⁰ is a protecting group.

The presented invented compounds can also be bound to a carrier material (solid support), if Z possesses a free or a protected OH function. A wide selection of carrier materials can be used, for instance silica, Porasil C, polystyrene, Controlled Pore Glass (CPG), Kieselgur, poly(dimethylacrylamide), poly(acrylmorpholino), Cellulose, Fractosil 500. Depending on the type of carrier materials different functionalities for the anchor are used. Substituted alkyl or aryl silyl compounds are used for silicon carrier materials like Silica and glass to form a siloxan or siloximine anchor. Ethers, esters, amines, amides, sulfides, sulfones and phosphates can be used by organic polymers.

In the case that Y² is a group of the formula (III), in which X³ is equivalent to O⁻ and X⁴ is equivalent to H, the above mentioned compounds represent H-phosphonates and are employed in the H-phosphonate method for the oligonucleotide synthesis (Sinha und Cook, Nucleic Acids Research (1988) 16:2659-2669). H-phosphonates may be converted to phosphit diesters, phosphorothioates, or phosphoramidates, as soon they are incorporated at the 5′ end of the oligonucleotide (Miller et al., Nucleic Acids Res. (1983) 11:5189-5204, Eckstein, Ann. Rev. Biochem. (1985) 54:367-402).

Accordingly, the above mentioned compounds in which Y² is a group of the formula (III) in which X³ is equivalent to O⁻ and X⁴ is equivalent to R¹⁰O— can be used in the phosphotriester method for oligonucleotide synthesis (Garegg, et al., Chemica Scripta (1985) 26:5).

The compounds in which Y² represents a group of the formula (II), in which X¹ is equivalent to chlorine and X²is equivalent to R⁷O—, are phosphochloridites and are used in the phosphochloridite technique for oligonucleotide synthesis (Wada et al., J. Org. Chem. (1991) 56:1243-1250).

The phosphoramidites in which Y² is equivalent to the above formula (II) are especially preferred for the purpose of the presented invention.

R¹ and R² are the same or different H or sulfur protecting groups. Preferred sulfur protecting groups are for example trityl, 4,4′-dimethoxytrityl, 4-monomethoxytrityl, 9-fluorenylmethyl (Ponsati, B., et al., Tetrahedron, 46, 8255-8266, 1990), 9-fluorenylmethoxycarbonyl, 2,4-dinitrophenylethyl, 2,4,6-trimethoxybenzyl (Munson, M. C. et al., J. Org. Chem., 57, 3013-3018, 1992), 4-methoxybenzyl and allyloxycarbonylaminomethyl (Kimbonguila, A. M., et al., Tetrahedron 55, 6931-6944, 1999). Especially preferred is 4,4′-dimethoxytrityl. Further protecting groups can be found in Lloyd-Williams, P. et al., Chemical Approaches to the Synthesis of Peptides and Proteins, New York, CRC Press. The sulfur protecting groups trityl and acetamidomethyl can be cleaved by iodine oxidation (Kamber et al., Helvetica Chimica Acta, Vol. 63, No. 96, 899-915, 1980). The sulfur protecting groups 4,4′-dimethoxytrityl and 4-monomethoxytrityl can be cleaved by AgNO₃ in methanol (Huang, Z. and Benner, S. A., Synlett, 83-84, 1993). The 4,4′-dimethoxytrityl sulfur protecting group can also be cleaved under mild acid conditions (i.e. 2% dichloro acetic acid in dichloromethane), that is compatible to the oligonucleotide synthesis. The great variety of sulfur protecting groups offers the opportunity to select orthogonal protecting groups , whose deprotection conditions are compatible to the oligonucleotide synthesis to introduce different labels.

According to a preferred embodiment of the presented invention the rest R⁷ represents a base labile protecting group.

In a particularly preferred embodiment R⁷ is a base labile protecting group selected from β-cyanoethyl, β-nitroethyl, 2,2,2-trichlorethyl, methyl, 1,1-dimethyl-2,2,2-thrichlorethyl, 2,2,2-tribromethyl, benzyl, o-chlorphenyl, p-nitrophenylethyl, 2-methylsulfonylethyl and 1,1-dimethyl-2-cyanoethyl.

According to an especially preferred embodiment of the presented invention where R⁷ is a base labile protecting group R⁸ and R⁹ are individually alkyl consisting of 1 to 16 C atoms, cycloalkyl consisting of 3 to 8 C atoms, aryl consisting of 6 to 20 C atoms; or R⁸ and R⁹ are joined together to form with a N atom a cyclic structure with 4 to 7 C atoms, in which a C atom of the cyclic structure can be replaced by O or S. Moreover it is especially preferred, if R⁸ and R⁹ are independently from each other alkyl consisting of 1 to 6 C atoms. Also especially preferred is where R⁸ and R⁹ are isopropyl, butyl, hexyl, nonyl, dodecyl, hexadecyl, cyclopropyl, cyclobutyl, cyclohexyl, cyclooctyl, phenyl, tolyl, benzyl, xylyl, naphthyl, morpholino, piperidinyl or thiomorpholino.

Further protecting groups R⁸ and R⁹ are listed in Green, T. W., Protective Groups in Organic Chemistry, New York: Wiley & Sons, 1981.

According to a preferred embodiment of the presented invention, Z is a hydrocarbon structure consisting of 2 to 28 C atoms, in which Z also includes the heteroatoms of the elements N, O, P and S.

According to a further preferred embodiment of the presented invention, Z is a hydrocarbon structure consisting of 2 to 28 C atoms, in which Z also includes the heteroatoms of the elements N, O and P.

According to a further preferred embodiment of the presented invention, Z is a hydrocarbon structure consisting of 2 to 28 C atoms, in which Z also includes the heteroatoms of the elements N and O.

According to a further preferred embodiment of the presented invention, Z is a hydrocarbon structure consisting of 2 to 28 C atoms, where Z can also include the heteroatoms of the elements N and O, in which the elements N and O are solely present as part of an amide bond.

According to a further preferred embodiment of the presented invention, Z is a hydrocarbon structure consisting of 2 to 28 C atoms, in which Z also includes the heteroatoms of the elements P and 0.

According to a further preferred embodiment of the presented invention, Z is a hydrocarbon structure consisting of 2 to 28 C atoms, where Z can also include the heteroatoms of the elements P and O, in which the elements P and O are solely present as part of a phospor diester bond.

According to a further preferred embodiment of the presented invention, Z is a hydrocarbon structure consisting of 2 to 8 C atoms.

According to an especially preferred embodiment of the presented invention, Z is a hydrocarbon structure consisting of 4 C atoms and 6 H atoms.

According to an especially preferred embodiment of the presented invention compounds of the formula

are provided, where A¹, A², A³, A⁴, A⁵, A⁶ are the same or different alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms, cycloalkyl of 1-22 C atoms, H, protecting-group-Y¹ or group Y², where A¹, A², A³, A⁴, A⁵, A⁶ can also include protecting-group-Y¹ and group Y² and where protecting-group Y¹ as well as group Y² is present at least once.

The compounds according to formula (IV) possess at least two further functional groups besides both S atoms. Moreover the substitutes A¹, A², A³, A⁴, A⁵ and A⁶ can be a functional group. A¹, A², A³, A⁴, A⁵ and A⁶ can also be alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms or H, in the case that out of the six substitutes A¹, A², A³, A⁴, A⁵ and A⁶ not less than two of the substitutes are functional groups, at least the missing functional group(s) must be bound to the above defined heteroalkyl(s). At least one of these functional groups is protected by a protecting group.

Preferred are compounds, where A² and A⁴ are equal to protecting-group-Y¹ or Y², where A², A⁴ can also include protecting-group-Y¹ and group Y² and where protecting-group-Y¹ as well as group Y² are present at least once. In the case that compounds of the structure (IV) are present, where A¹, A³, A⁵ and A⁶ are alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms, cycloalkyl of 1-22 C atoms or H. A² and A⁴ are functional groups or include a functional group. The substitute, which is not a functional group, is a heteroalkyl of 1-22 C atoms or a cycloheteroalkyl of 1-22 C atoms including at least one functional group. At least one of these functional groups is protected by a protecting group. Should A² or A⁴ include two functional groups, the substitute not including a functional group can be an alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms, cycloalkyl of 1-22 C atoms or H.

Especially preferred are compounds, where A², A⁴ are identical to protecting-group-Y¹, Y², where A² is not identical to A⁴. In that case compounds of the structure (IV) are present, where A¹, A³, A⁵ and A⁶ are alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms, cycloalkyl of 1-22 C atoms or H. A² and A⁴ are functional groups. At least one of these functional groups is protected by a protecting group.

Especially preferred are compounds, where A¹, A³, A⁵ and A⁶ are identical to H. In that case compounds of the structure (IV) are present, where A¹, A³, A⁵ and A⁶ are H and A² and A⁴ are a functional group. At least one of these functional groups is protected by a protecting group.

Also preferred are compounds of the structure (IV), where protecting-group-Y¹ is identical to protecting-group-OOC, protecting-group-O, protecting-group-S, protecting-group-NH or protecting-group-NR^(y) and Y² is identical to COOH, COOR^(x), OH, OR^(x), SH, SR^(x), NH₂, NHR^(x), NR^(x)R^(y), where R^(x) is a protecting group and R^(y) is an alkyl of 1-15 C atoms, an aryl of 1-14 C atoms, a cycloalkyl of 1-15 C atoms, a heteroalkyl of 1-15 C atoms, a protecting group or a group of the formula (II) or (III).

Most especially preferred are compounds of the structure (IV), where A² is identical to protecting-group-O, protecting-group-OOC or protecting-group-NH, where A⁴ is identical to COOH, a group of the formula (II) or (III) or protecting-group-NH, and R¹═R²=DMT or both S atoms are joined together to form a disulfide bridge and in that case R¹, R² do not exist.

According to an especially preferred embodiment of the presented invention compounds of the formula

are provided, where D¹, D², D³, D⁴, D⁵, D⁶ are the same or different alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms, cycloalkyl of 1-22 C atoms, H, protecting-group-Y¹ or group Y², where D¹, D², D³, D⁴, D⁵, D⁶ can also include protecting-group-Y¹ and group Y² and where protecting-group-Y¹ as well as group Y² is present at least once.

In addition to containing both S groups, compounds according to formula (V) have at least two further functional groups. Moreover the substitutes D¹, D², D³, D⁴, D⁵ and D⁶ can be a functional group. D¹, D², D³, D⁴, D⁵ and D⁶ can also be alkyl of 1-22C atoms, heteroalkyl of 1-22 C atoms, cycloalkyl of 1-22 C atoms or H, in the case that out of the six substitutes D¹, D², D³, D⁴, D⁵ and D⁶ not less than two of the substitutes are functional groups, at least the missing functional group(s) must be bound to the above defined heteroalkyl(s). At least one of these functional groups is protected by a protecting group. R¹ and R² are as defined above.

Also preferred are compounds of the structure (V), where D¹, D³ and D⁵ are alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms, cycloalkyl of 1-22 C atoms or H. The substitutes D², D⁴, D⁶ can be a functional group. D², D⁴ and D⁶ can also be alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms or cycloalkyl of 1-22 C atoms or H, in the case that out of the three substitutes D², D⁴ and D⁶ not less than two of the substitutes are functional groups, at least the missing functional group(s) must be bound to one of the above defined heteroalkyl(s). At least one of these functional groups is protected by a protecting group.

Also preferred are compounds of the structure (V), where D² or D⁴ or D⁶ is identical to protecting-group-Y¹ or Y² and D² or D⁴ or D⁶ include the groups protecting-group-Y⁰¹ or Y², where protecting-group-Y¹ as well as group Y² are present at least once.

Also preferred are compounds of the structure (V), where D¹, D², D³ and D⁵ are identical to H and D⁴ and D⁶ include the groups protecting-group-Y¹ and Y²,

Also preferred are compounds of the structure (V), where protecting-group-Y¹ is identical to protecting-group-OOC, protecting-group-O, protecting-group-S, protecting-group-NH or protecting-group-NR^(y) and Y² is identical to COOH, COOR^(x), OH, OR^(x), SH, SR^(x), NH₂, NHR^(x) or NR^(x)R^(y), where R^(x) is a protecting group and R^(y) is an alkyl of 1-15 C atoms, an aryl of 1-14 C atoms, a cycloalkyl of 1-15 C atoms, a heteroalkyl of 1-15 C atoms, a protecting group or a group of the formula (II) or (III).

Also preferred are compounds of the structure (V), where D¹, D², D³ and D⁵ are identical to H and D⁴ and D⁶ are protecting-group-Y¹, Y².

Also preferred are compounds of the structure (V), where D¹, D², D³, D⁴ and D⁵ are identical to H and D⁵ is heteroalkyl of 1-22 C atoms or cycloheteroalkyl of 1-22 C atoms, where D⁶ include the groups protecting-group-Y¹ and Y², where R¹═R²=DMT or both S atoms are joined together to form a disulfide bridge and in that case R¹, R² do not exist.

Also especially preferred are compounds of the structure (V), where D¹, D², D³ and D⁵ are H. D⁴ or D⁶ are a functional group. The substitute that is not a functional group is a heteroalkyl of 1-22 C atoms or a cycloheteroalkyl of 1-22 C atoms with at least one functional group. At least one of these functional groups is protected by a protecting group.

Also especially preferred are compounds of the structure (V), where D¹, D², D³ and D⁵ are H. The substitutes D⁴ and D⁶ are alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms, cycloalkyl of 1-22 C atoms or H, with the restriction that at least two functional groups are bound amongst D⁴ and D⁶. At least one of these functional groups is protected by a protecting group.

Especially preferred are the functional groups COOH, COOR^(x), OH, OR^(x), SH, SR^(x), NH₂, NHR^(x) and NR^(x)R^(y), where R^(x) represents a protecting group and R^(y) is alkyl of 1-15 C atoms, heteroalkyl of 1-15 C atoms, aryl of 1-14 C atoms, cycloakyl of 1-15 C atoms, or a protecting group, which can be cleaved independently of R^(x3) or a group of the formula (II) or (III).

Most especially preferred are compounds of the structure (V), where D¹, D², D³, D⁴ and D⁵ are H. D⁶ is a hteroalkyl of 1-22 C atoms or a cycloheteralkyl of 1-22 C atoms including a total of at least two functional groups, at least one of which is protected by a protecting group. The functional groups are a group of formula (II) or OR^(x), COOR^(x), COOH or NHR^(x), where R^(x) is DMT, Fmoc or an alkyl of 1-22 C atoms. R¹═R²=DMT or R¹ and R² do not exist, if both S atoms are joined together to form a disulfide bridge.

According to an especially preferred embodiment of the presented invention compounds of the formula

are provided, where B¹, B², B³ and B⁴ are identical or different alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms, cycloalkyl of 1-22 C atoms, H, protecting-group-Y¹ or group Y², where B¹, B², B³and B⁴ can also include protecting-group-Y¹ and group Y² and where protecting-group-Y¹ as well as group Y² is present at least once.

In addition to containing both S groups, compounds of formula (VI) have at least two further functional groups. Further the substitutes B¹, B², B³, B⁴ can be a functional group. B¹, B², B³ and B⁴ can also be alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms, cycloalkyl of 1-22 C atoms or H, in the case that out of the four substitutes B¹, B², B³, B⁴ not less than two of the substitutes are functional groups, at least the missing functional group(s) must be bound to the above defined heteroalkyl(s). At least one of these functional groups is protected by a protecting group.

Especially preferred are compounds of the structure (VI), where B² or B⁴ is identical to protecting-group-Y¹ or Y² and either B² or B⁴ include the groups protecting-group-Y¹ or Y², where protecting-group-Y¹ as well as group Y² are present at least once.

Also especially preferred are compounds of the structure (VI), where B¹, B² and B³ are identical to H and B⁴ include the groups protecting-group-Y¹ and Y².

Also especially preferred are compounds of the structure (VI), where B⁴ is a heteroalkyl of 1-22 C atoms or a cycloheteroalkyl of 1-22 C atoms, where B⁴ includes the groups protecting- group-Y¹ and Y², where protecting-group-Y¹ is identical to protecting-group-OOC, protecting-group-O or protecting-group-NH and Y² is identical to COOH, COOR^(x), OR^(x), NHR^(x) or a group of formula (II), where R^(x) is identical to DMT or Fmoc and R¹═R²=DMT or both S atoms are joined together to form a disulfide bridge and in that case R¹, R² do not exist.

Also especially preferred are compounds of the structure (VI), where B¹ and B³ are alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms, cycloalkyl of 1-22 C atoms or H. B² and B⁴ are a functional group. At least one of these functional groups is protected by a protecting group.

Also especially preferred are compounds of the structure (VI), where B¹ and B³ are alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms, cycloalkyl of 1-22 C atoms or H. B² or B⁴ are functional groups. The substitute that is not a functional group is a heteroalkyl of 1-22 C atoms or a cycloheteroalkyl of 1-22 C atoms with at least one functional group. At least one of these functional groups is protected by a protecting group.

Also especially preferred are compounds of the structure (VI), where B¹ and B³ are alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms, cycloalkyl of 1-22 C atoms or H. The substitutes B² and B⁴ are alkyl of 1-22 C atoms, heteroalkyl of 1-22 C atoms, cycloalkyl of 1-22 C atoms or H, with the restriction that at least two functional groups are bound amongst B² and B⁴. At least one of these functional groups is protected by a protecting group.

Also especially preferred are compounds of the structure (VI), where B¹, B², B³ are H. B⁴ is a heteroalkyl of 1-22 C atoms or a cycloheteroalkyl of 1-22 C atoms including a total of at least two functional groups, of which at least one is protected by a protecting group. The functional groups are COOH, COOR^(x), OH, OR^(x), SH, SR^(x), NH₂, NHR^(x), NR^(x)R^(y), where R^(x) represents a protecting group and R^(y) is alkyl of 1-15 C atoms, heteroalkyl of 1-15 C atoms, aryl of 1-14 C atoms, cycloalkyl of 1-15 C atoms or a protecting group, which can be cleaved independently of R^(x) or a group of formula (II).

Also especially preferred are compounds of the structure (VI), where B¹, B², B³ are H. B⁴ is a heteroalkyl of 1-22 C atoms or a cycloheteroalkyl rest of 1-22 C atoms including a total of at least two functional groups, of which at least one is protected by a protecting group. The functional groups are a group of formula (II) or OR^(x), COOR^(x), COOH or NHR^(x), where R^(x) is DMT, Fmoc or an alkyl of 1-22 C atoms. R¹═R²=DMT or R¹ and R² are not present, if both S atoms are joined together to form a disulfide bridge.

The presented invention includes also the application of the invented compounds for the modification of oligomers. In addition the presented invention also includes the application of the invented compounds for the immobilisation of modified oligomers on surfaces. Furthermore the presented invention also includes the application of the invented compounds for the conjugation of enzymatic, chromogene, fluorogene, radioactive or chemiluminiscent labels, substances intercalating in nucleic acids, metals, metal ions, hormones, proteins, peptides, nucleolytic and proteolytic agents, biotin, antigens, haptens, antibodies or receptors to molecules or oligomers. Finally the invention also includes the application of the invented compounds for the automatic synthesis of oligomers.

Within the described applications of the invented compounds it is especially preferred that the oligomers used are oligonucleotides, polypeptides, PNA or LNA (Locked Nucleic Acid).

The synthesis of oligonucleotides which are modified with the invented compounds takes place in solution or preferably at solid phase, if necessary using an automated synthesiser.

A SHORT DESCRIPTION OF THE DRAWINGS

FIG. 1 synthesis scheme according to example 4;

FIG. 2 SPR kinetic for the immobilization of oligonucleotides onto a gold surface according to example 13;

FIG. 3 tests for stability of an oligonucleotide on a gold surface according to example 13;

FIG. 4, FIG. 4.1 and FIG. 4.2 show the results of a square wave voltammetric measurement to prove the hybridizability of the oligonucleotides on a gold surface according to example 13;

FIG. 4.3 and FIG. 4.4 show the results of cyclovoltammetric measurements to quantify the hybridizability of the oligonucleotides on a gold surface according to example 13;

FIG. 5 Shows the extension of the surface coverage by oligonucleotides on a gold surface by integration of the peak areas of the cyclovoltammograms according to example 13;

FIG. 6 synthesis scheme according to example 15;

FIG. 7 synthesis scheme according to example 16;

FIG. 8 synthesis scheme according to example 17;

FIG. 9 synthesis scheme according to example 18.

POSSIBILITIES FOR REALISING THE INVENTION EXAMPLE 1 Synthesis of 3-O-(4,4′-dimethoxytrityl)-1,4-bis-(4,4′-dimethoxitrityl)-sulfanyl-butan-2-ol

In an argon atmosphere 2.0 g (12.9 mmol) of 1,4-Dithio-butan-2,3-diol is dissolved by stirring in 35 ml anhydrous pyridine in a round-bottomed 250 ml flask. 15.3 g (45.15 mmol) of DMT-Cl (4,4′-Dimethoxytrityl Chloride) is added to the clear solution. After 2 hours stirring at room temperature the reaction mixture is heated to 50° C. and is stirred overnight. Thereafter MeOH (2 ml) is added and stirred for 10 min. After concentration in high vacuum the residue is dissolved in 200 ml DCM and is then extracted once with a 1 mol/l NaHCO₃ solution and once with a NaCl solution. The organic phase is dried with Na₂SO₄, filtered and concentrated. For purification of the raw material silica gel 60 is used for chromatography (eluent: ethylacetate/n-heptane/1%Et₃N). The product containing fractions are collected and the solvent is evaporated to dryness under vacuum. TLC (silica gel, EtOAc/n-heptane=1:2, +1% Et₃N): R_(f)=0.20.

5.90 g (43.2% of the theoretical yield) of a yellowish foaming residue is obtained.

¹³C-NMR (CD₃Cl) δ (ppm): 33.21 (C-4), 35.82 (C-1), 55.17 (OCH₃), 65.50 and 65.82 (C-2 and C-3), 71.52 and 75.02 (S—C_(q) DMT), 87.03 (O—C_(q) DMT), 113.01, 126.32, 127.71, 129.30, 131.03, 136.21, 137.13, 145.25, 145.76, 146.10, 157.72, 158.61 (C_(arom) DMT).

¹H-NMR (CD₃Cl) δ (ppm): 2.05-2.21 (m, 4H, CH₂-1 und CH₂-4), 3.17 (m, 1H, H-3), 3.65 (m, 1H, H-2), 6.72-7.38 (m, 39H_(arom) DMT).

EXAMPLE 2 Synthesis of 3-O-(4,4′-Dimethoxytrityl)-1,4-bis-(4,4′-dimethoxitrityl)-sulfanyl-butan-2-O-(2-cyanoethyl)-N,N′-diisopropylphosphoramidite

In an argon atmosphere 503 mg (0.47 mmol) of 3-O-(4,4′-dimethoxytrityl)-1,4-bis-(4,4′-dimethoxitrityl)sulfanyl-butan-2-ol are dissolved in 4 ml anhydrous ACN. The solution is cooled with ice and 753.2 μl (4.4 mmol) of N,N′-diisopropylethylamine are added dropwise while stirring. 295 μl (1.32 mmol) of chlor-(2-cyanoethoxy)(diisopropylamino)-phosphine are added dropwise using a syringe. After 1,5 hours stirring at room temperature the reaction mixture is diluted with 30 ml DCM and is extracted once with a 1 mol/l NaHCO₃ solution and once with a saturated sodium chloride solution. The organic phase is dried with Na₂SO₄, filtered and concentrated. For purification of the raw material silica gel is used for chromatography (eluent: gradient ethlyacetate/n-heptane 3:1 to 2:1 in the presence of 1% Et₃N). Both diastereomeres can be distinguished by TLC as well as by ³¹P-NMR: TLC (silica gel, EtOAc/n-heptane=1:2, +1% Et₃N): R_(f)(2 diastereomeres)=0.20; 0.27

331.3 mg (55.4% of the theoretical yield) of a white foaming residue is obtained.

³¹P-NMR (CD₃Cl) δ (ppm): 149.65, 148.59

MS (EI): 303 (DMT⁺), 1003.1 (M+Na⁺)

EXAMPLE 3 Synthesis of 5-O-(4,4′-dimethoxytrityl)-(1,2)-dithian-4-ol

A solution of I₂ in DCM (9.4 mmol I₂ in 120 ml DCM) is added to a solution of 2 g (1.88 mmol) 3-O-(4,4′-dimethoxytrityl)-1,4-bis-(4,4′-dimethoxitrityl)sulfanyl-butan-2-ol and 5 ml pyridine in 100 ml DCM at room temperature. After 10 min of stirring, 200 ml of a 0.5 N Na₂S₂O₃ solution is added. The layers are separated, the organic phase extracted three times with H₂O and the combined organic phases dried with Na₂SO₄. The solvent is evaporated and the remaining foam purified by silica gel chromatography (eluent: gradient of 10-30% EtOAc in n-heptane in presence of 1% Et₃N). TLC (silica gel, EtOAc/n-heptane=1:2, +1% Et₃N): R_(f)(2 diasteromeres)=0.31; 0.40.

710.7 mg (83.6% of the theoretical yield) of a yellowish oil is obtained.

¹³C-NMR (CD₃Cl) δ (ppm): 32.76 (C-6), 41.83 (C-3), 55.24 (OCH₃), 67.21 (C-5), 72.32 (C-4), 87.25 (C_(q) DMT), 113.16, 126.64, 127.89, 129.39, 130.61, 136.94, 145.14, 158.09 (C_(arom) DMT).

¹H-NMR (CD₃Cl) δ (ppm): 2.75 (m, 2H, CH₂-6), 3.03 (m, 2H, CH₂-3), 3.69 (m. 2H, H-4, H-5), 3.79 (s, 3H, OCH₃), 6.83-7.52 (m, 13H_(arom) DMT).

MS (electrospray ionisation in MeOH): 303 (DMT⁺), 477 (M+Na⁺).

EXAMPLE 4 Synthesis of 5-O-(4,4′-dimethoxytrityl)-(1,2)-dithian-4-O-(2-cyanoethyl)-N,N′-diisopropylphosphoramidite

A schematic overview of the synthesis is shown in FIG. 1.

In an argon atmosphere 500 mg (1.1 mol) of 5-O-(4,4′-dimethoxytrityl)-(1,2)-dithian-4-ol is dissolved in 8 ml of anhydrous DCM. The solution is cooled with ice and 753.2 μl (4.4 mmol) of N,N′-diisopropylethylamine is added dropwise while stirring. Using a syringe 295 μl (1.32 mmol) of chlor-(2-cyanoethoxy)(diisopropylamino)-phosphine is added dropwise. After 1 hour of stirring at room temperature the reaction mixture is diluted with 50 ml DCM and is extracted once with a 1 mol/l NaHCO₃ solution and once with a saturated sodium chloride solution. The organic phase is dried with Na₂SO₄, filtered and concentrated. For purification of the raw material silica gel chromatography is used (eluent: gradient from 5-15% EtOAc in n-heptane in presence of 1% Et₃N). Both diastereomeres can be distinguished by TLC as well as by ³¹P-NMR: TLC (silica gel, EtOAc/n-heptane=1:2, +1% Et₃N): R_(f)(2 diastereomeres)=0.31; 0.40

459.6 mg (63.8% of the theoretical yield) of the desired product is obtained as a yellowish oil.

³¹P-NMR (CD₃Cl) δ (ppm): 148.33, 150.19.

MS (EI): 303 (DMT⁺), 655 (M), 677 (M+Na⁺)

EXAMPLE 5 Synthesis of 1,4-bis-(4,4′-dimethoxitrityl)sulfanyl-butan-2,3-diol

In an argon atmosphere 2.2 g (14.3 mmol) of 1,4-dithio-butan-2,3-diol are dissilved by stirring in 40 ml anhydrous pyridine in a round-bottomed 250 ml flask. 9.93 g (29.3 mmol) of DMT-Cl (4,4′-Dimethoxytrityl Chloride) is added to the clear solution. After 2 hours stirring at room temperature 2 ml MeOH is added and the mixture is stirred a further 5 min. The solvent is evaporated, the residue is dissolved in 50 ml DCM and is extracted once with a 1 mol/l NaHCO₃ solution and once with a NaCl solution. The organic phase is dried with Na₂SO₄, filtered and concentrated. The remaining foam is purified by silica gel chromatography (eluent: gradient of 10-30% ethylacetate/n-heptane in presence of 1% Et₃N). The product containing fractions are collected and the solvent is evaporated to dryness under vacuum. TLC (silica gel, EtOAc/n-heptane=1:2, +1% Et₃N): R_(f)=0.35.

8.66 g (79.8% of the theoretical yield) of a white, foaming residue is obtained.

¹³C-NMR (CD₃Cl) δ (ppm): 34.83 (C-1, C-4), 55.20 (OCH₃ DMT), 65.94 (C-2, C-3), 71.70 (C_(q) DMT), 113.23, 126.61, 127.95, 129.40, 130.62, 136.96, 145.14, 158.09 (C_(arom) DMT).

¹H-NMR (CD₃Cl) δ (ppm): 2.01 (m, 2H, OH-2, OH-3), 2.35 (m, 4H, C-1, C-4), 3.05 (m, 2H, C-2, C-3), 3.73 (s, 12H, OCH₃), 6.78-7.45 (m, 26H_(arom) DMT).

EXAMPLE 6 Synthesis of 3-O-(9-fluorenylmethoxycarbonyl)-1,4-bis-(4,4′-dimethoxitrityl)sulfanyl-butan-2-ol

In an argon atmosphere 407 mg (1.58 mmol) of 9-Fluorenylmethylchloroformate is added to a solution of 1 g (1.32 mmol) of 1,4-bis-(4,4′-dimethoxitrityl)sulfanyl-butan-2,3-diol in 10 ml anhydrous pyridine. The reaction mixture is stirred overnight at room temperature. Then 500 μl MeOH is added and stirred for 10 min. After concentration of the solvent the residue is dissolved in 30 ml DCM and extracted once with a NaCl solution. After the drying of the organic phase with Na₂SO₄ and evaporation of the solvent, the raw material is purified by silica gel chromatography (eluent: ethylacetate/n-heptane=3:1). TLC (silica gel, EtOAc/n-heptane=1:2): R_(f)=0.25.

303 mg (23.4% of the theoretical yield) of a white foaming residue is obtained.

¹³C-NMR (CD₃Cl) δ (ppm): 31.68 (C-4), 35.06 (C-1), 55.20 (OCH₃ DMT), 50.36 (CH-Fmoc), 65.31 and 65.45 (C-2 and C-3), 66.77 (CH₂-Fmoc), 70.38 (2S-C-DMT), 113.23, 120.05, 124.70, 127.06, 127.6, 128.08, 129.22, 136.24, 136.82, 141.51, 143.31, 144.35, 145.01, 154.36, 158.10, 158.3 (C_(arom) DMT and Fmoc).

¹H-NMR (CD₃Cl) δ (ppm): 2.10-2.45 (m, 4H, CH₂-1, CH₂-4), 3.73 (d, 12H, OCH₃ DMT), 3.98-4.35 (m, 2H, H-3, H-2), 6.78-7.82 (m, 34H, H_(arom) DMT and Fmoc).

MS (electrospray ionisation): 303.2 (DMT⁺), 1283.3 (M+Na⁺)

EXAMPLE 7 Synthesis of 5-O-(9-fluorenylmethoxycarbonyl)-(1,2)-dithian-4-ol

A solution of I₂ in DCM (6.25 mmol I₂ in 60 ml DCM) is added to a solution of 1.23 g (1.25 mmol) 3-O-(9-fluorenylmethyloxycarbonyl)-1,4-S,S′-bis-(4,4′-dimethoxitrity)-butan-2-ol in 50 ml DCM at room temperature. After 10 min 100 ml of 0.5 N Na₂S₂O₃ solution is added during rapid stirring. The layers are separated, the organic phase is extracted three times with H₂O and the combined organic phases are dried with Na₂SO₄. The solvent is evaporated and the remaining foam is purified by silica gel chromatography (eluent: gradient of 10-30% EtOAc in n-heptane). TLC (silica gel, EtOAc/n-heptane=1:2): R_(f)=0.20.

212 mg (45.3% of the theoretical yield) of a yellow oil is obtained.

¹³C-NMR (CD₃Cl) δ (ppm): 34.51 (C-6), 41.86 (C-3), 46.74 (CH-Fmoc), 65.18 (CH₂-Fmoc), 70.11 (C-5), 72.21 (C-4), 120.06, 125.07, 127.59, 127.98, 141.33, 143.18 (C_(arom) Fmoc)

¹H-NMR (CD₃Cl) δ (ppm): 2.98 (m, 2H, CH₂-6), 3.09 (m, 2H, CH₂-3), 3.72 (m, 2H, H-4, H-5), 7.28-7.80 (m, 8H_(arom) Fmoc).

EXAMPLE 8 Synthesis of 3-O-(9-fluorenylmethoxycarbonyl)-1,4-bis-(4,4′-dimethoxitrityl)sulfanyl-butan-2-O-(2-cyanoethyl)-N,N′-diisopropylphosphoramidite

In an argon atmosphere 460 mg (0.47 mmol) of 3-O-(9-fluorenylmethoxycarbonyl)-1,4-bis-(4,4′-dimethoxitrityl)sulfanyl-butan-2-ol is dissolved in 5 ml of anhydrous DCM. 322 μl (1.88 mmol) of N,N′-diisopropylethylamine is added to the ice cooled solution dropwise while stirring. 136.5 μl (0.61 mmol) of chlor-(2-cyanoethoxy)(diisopropylamino)-phosphine is added dropwise using a syringe. After 1 hour of stirring at room temperature the reaction mixture is diluted with 50 ml DCM and is extracted once with a 1 mol/l NaHCO₃ solution and once with a saturated sodium chloride solution. The organic phase is dried with Na₂SO₄, filtered and concentrated. For purification of the raw material silica gel chromatography is used (eluent: gradient from 5-20% EtOAc in n-heptane in presence of 1% Et₃N). Both diastereomeres can be distinguished by TLC as well as by ³¹P-NMR: TLC (silica gel, EtOAc/n-heptane=1:2, +1% Et₃N): R_(f)(2 diastereomeres)=0.26; 0.29

270 mg (48.7% of the theoretical yield) of a white foaming residue is obtained.

³¹P-NMR (CD₃Cl) δ (ppm): 149.35, 150.29.

EXAMPLE 9 Synthesis of 5-O-(9-fluorenylmethoxycarbonyl-(1,2)-dithianyl-4-O-(2-cyanoethyl)-N,N′-diisopropylphosphoramidite

In an argon atmosphere 500 mg (1.33 mmol) of 5-O-(9-fluorenylmethoxycarbonyl)-(1,2)-dithianyl-4-ol is dissolved in 5 ml of anhydrous DCM. 914 μl (5.32 mmol) of N,N′-diisopropylethylamine are added dropwise to the ice cooled solution while stirring. 387 μl (1.73 mmol) of chlor-(2-cyanoethoxy)(diisopropylamino)-phosphine is added dropwise using a syringe. After 1.5 hour of stirring at room temperature the reaction mixture is diluted with 50 ml DCM and is extracted once with a 1 mol/l NaHCO₃ solution and once with a saturated sodium chloride solution. The organic phase is dried with Na₂SO₄, filtered and concentrated. For purification of the raw material silica gel chromatography is used (eluent: gradient from 5-20% EtOAc in n-heptane in presence of 1% Et₃N). Both diastereomeres can be distinguished by TLC as well as by ³¹P-NMR: TLC (silica gel, EtOAc/n-heptane=1:2, +1% Et₃N): R_(f)(2 diastereomeres)=0.22; 0.3

295 mg (48.7% of the theoretical yield) of a white foaming residue is obtained.

³¹P-NMR (CD₃Cl) δ (ppm): 149.04, 150.32

EXAMPLE 10 Solid Phase Synthesis of Thiol Modified Oligonucleotides by the Phosphoramidite Method Using the Compound as Described in Example 4

The synthesis of the oligodesoxyribonucleotides was carried out in a 1 μmol synthesis scale using the solid phase phosphoramidite technique with an automated DNA/RNA synthesizer model 384 B (Applied Biosystems) on ®CPG (Controlled Pore Glass), on which the first nucleoside unit was attached by the 3′ end. For this the synthesis instrument is for example mounted with reaction columns which are filled with a carrier material preloaded with a nucleobase. In a first reaction step the 5′OH protecting group (4,4′-dimethoxytrityl) is cleaved by treatment with a solution of 2% dichloracetic acid in dichlormethane. After washing the column with acetonitril the coupling of the next building block which can be the modified amidite of example 4 is achieved at the free 5′-OH function by activation with tetrazole in acetonitril. For incorporation of the modified amidite respectively a 10 min double coupling step is used. The existing still trivalent P atom is transferred after renewed washing into the natural pentavalent phosphate by oxidation with a solution of Iodine in THF/Lutidin/H₂O. The following capping step by acetic anhydride/1-methylimidazole blocks free 5′-OH groups by acetylation. Thus the building of failure sequences are suppressed. After washing the synthesis cycle starts over again with renewed cleavage of the 5′-O-dimethoxytrityl protecting group. In this way the modified oligonucleotide is built up. The last DMT group was not cleaved. After completed synthesis the oligonucleotide bound to the carrier was set free by treatment with concentrated ammoniac solution in water. The protecting groups at the heterocycles were removed in the same solution within 16 h at 37° C. The samples were concentrated to approx. 200 μl in vacuum and purified by HPLC.

EXAMPLE 11 Solid Phase Synthesis of Thiol Modified Oligonucleotides by the Phosphoramidite Method Using the Compound as Described in Example 9

The oligomer synthesis takes place as described in example 10. For the deprotection of the Fmoc group the oligonucleotide at the carrier is treated with a solution of 0.5 mol/l DBU in acetonitril (4×1 ml 0.5 mol/l DBU/ACN in 2 min). The work up procedure also follows that in example 10.

EXAMPLE 12 Solid Phase Synthesis of Thiol Modified Oligonucleotides by the Phosphoramidite Method Using the Compound as Described in Example 2

The oxidation step is carried out using a 0.1 mol/l iodine solution with extended reaction times (1 min). The further synthesis cycle and the work up procedure of the oligonucleotides is as described in example 10.

EXAMPLE 13 HPLC Purificaton of Trityl Protected Oligonucleotides

In the first purification step the DMT protected oligomers are purified by HPLC with a RP-C18 silica gel column (eluent: 0.1 mol/l triethylammoniumacetate buffer, acetonitril). The oligomers were treated with 100 μl of an 80% acetic acid solution and shaken for 20 min at room temperature. 100 μl H₂O und 60 μl 3 mol/l NaAc solution was added to that solution. The oligonucleotides were treated with 1.5 ml EtOH and completely precipitated at −20° C. (20 min). After centrifugation and decanting of the ethanol, the pellet is dried in vacuum. The characterisation of the oligomers was effected using MALDI-TOF MS. Table 1 shows the retention times of the synthesized oligonucleotides. TABLE 1 retention oligomer (5′->3′-direction) times (min) (sequence) with DMT oligonucleotide 1: 5′-XAGG TGA CTG TGT TAT CCG CA-3′ 10.05 oligonucleotide 2: 5′-XXAGG TGA CTG TGT TAT CCG CA-3′ 11.30 oligonucleotide 3: 5′-XXXAGG TGA CTG TGT TAT CCG CA-3′ 11.72 where X is compound 4 5′-XT10-3′ 21.12 5′-XXT10-3′ 21.52 where X is compound 2

EXAMPLE 14 Experiments for Immobilization of Oligonucleotides 1, 2 and 3 According to Example 13

Preparation of Single-Strand DNA Monolayer

a) Cleaning of Au Electrodes

To remove impurities on the gold surface the gold covered glas slides were immersed in a mixture (3:1) of concentrated sulfuric acid and hydrogen peroxide solution (30%) for 30 seconds. The electrodes were rinsed thoroughly with deionized water and placed in pure ethanol for 15 minutes.

b) Immobilization of Oligonucleotides 1, 2 and 3 on Gold Surfaces

Oligonucleotides were immobilized on gold surfaces overnight by self assembly from 30 μM solutions in 500 mM potassium phosphate buffer (pH 7.0). After adsorption the electrodes were rinsed thoroughly with potassium phosphate buffer.

Surface Plasmon Resonance spectroscopy (SPR) was used to examine the effectiveness of immobilization. SPR is highly sensitive to changes of refractive index at the metal interface that are a byproduct of adsorption and desorption processes. The shifting ΔΘ of the resonance angle is directly proportional to mass increase or decrease at the surface. Experiments were carried out with a Biosuplar II (from Analytical μ-Systems, Regensburg, Germany).

FIG. 2 illustrates the SPR kinetics of the immobilization of oligonucleotides oligo 1 ▪, oligo 2 (▴) and oligo 3 (●) onto a gold surface (c=30 μM in 500 mM potassium phosphate buffer, pH 7). It can be seen from the plot that oligonucleotides 1, 2 and 3 show roughly identical kinetic behaviour for the immobilization process. The amount adsorbed on the surface is less than that of comparable oligonucleotides with a single thiol anchor (□) (H₂N—C₆-TCG TCA CTG TCA GTG TCA GA-[C₃—S—S—C₃—OH] with C₃═(CH₂)₃ and C₆═(CH₂)₆), which reflects the higher spacial requirement per DNA strand.

c) Coadsorption of Alkane Thiols

The oligonucleotide-modified gold surface was treated with short-chain alkane thiols in order to put the DNA in a more upright position and to passivate gaps on the surface. This coadsorption was carried out for 30 minutes with a 1 mM solution of the corresponding thiol (propane thiol or 3-hydroxy propane thiol) in the above-mentioned potassium phosphate buffer containing 1% ethanol followed by a thorough rinsing with potassium phosphate buffer.

Stability Tests:

The stability of immobilization was checked by incubating the surfaces with phosphate buffer (pH 9) and applying conditions for dehybridization (2 mol/l NaOH) under SPR control. FIG. 3 illustrates a stability test for a monolayer of oligonucleotide 1 coadsorbed with propanethiol. At the point in time t=0 the oligonucleotide monolayer coadsorbed with propanethiol is subjected to 500 mM phosphate buffer at pH 7. At t=1 h the buffer was replaced with 500 mM phosphate buffer at pH 9. The resonance angle is shifted as a result of the higher refractive index of this buffer. Subsequently at t=2 h, the buffer was changed back to the original 500 mol/l phosphate buffer at pH 7 with the resonance angle also returning to its initial value. The amount of substance on the surface did not change during the treatment with buffer at pH 9. At t=5 h the buffer was replaced by 2 mol/l NaOH and finally at t=5.5 h again changed back to phosphate buffer, pH 7. Also when subjected to these conditions, the monolayer remains stable without any loss of material.

Verification of Hybridizability

In order to check the hybridizability, the above oligonucleotide monolayer was hybridized with a complementary strand double-labeled with ferrocenyl acetic acid ([FcAc—Y]₂—C GGA TAA CAC AGT CAC CT; Y=Amino Introducing Reagent with C3-spacer; Chemgene). The hybridization was performed by incubation of the monolayer with a 100 mmol/l sodium sulfate solution containing 1 μmol/l of complementary strand heated to 95° C., followed by cooling down over a period of at least 2 hours.

Square Wave and Cyclic voltammetric methods were employed for electrochemical characterization. Both methods can be used for the detection of surface-bound redox label (here ferrocenyl acetic acid).

With square wave voltammetry a linear voltage ramp is superimposed on a square wave potential at a frequency f and an amplitude E^(˜)(in the example f=10 Hz, E^(˜)=20 mV rms) and the current is detected at the end of every pulse. Through this the capacitive charging current is virtually eliminated, resulting in a voltammetric peak. A relative comparison is easily done, whereas absolute quantification is unproblematic.

With cyclic voltammetry a triangular voltage wave is driven and the resulting current is detected. Distinctive capactive charging currents can complicate the quantification of faradayic currents. However, the number of transferred charges and thus the number of redox labels can be determined by the integration of peak areas.

Using the square wave voltammetry described above it was checked whether the redox label of the hybridized complementary strand could be detected. The figures 4.1 and 4.2 illustrate the square wave voltammogram (f=10 Hz, E^(˜)=20 mV rms) for the oligonucleotide monolayer 1-3 coadsorbed with propanethiol (4.1) and hydroyx-propanethiol (4.2) and hybridized with the redox labeled complementary strand. All monolayers show a distinct peak at +0.23 V (vs Ag/AgCl/3M KCl), which is caused by oxidation of the ferrocenyl acetic acid on the complementary strand and indicates a successful hybridization of the monolayer. However the peak currents and consequently the hybridization efficiency varies depending on the coadsorption and oligonucleotide applied.

Cyclic voltammetry was used for quantification. By integration of the cyclic voltammograms (v=500 mV/s) in FIGS. 4.3 and 4.4 the number of redox labels and thus the surface concentration Γ of the complementary strand (roughness factor=2, number of labels per target=2) is determined and plotted in FIG. 5. The surface concentration Γ is in direct proportion to the hybrizability of the oligonucleotide monolayer.

Among the three oligonucleotides in example 13, oligonucleotide 2 shows the best hybridizability. The hybridizability of the ssDNA monolayer coadsorbed with hydroxypropanethiol is thus significantly higher as compared with the respective monolayer coadsorbed with propanethiol. The surface coverage is between 1·10⁻¹²−7·10¹² mol/cm² and is thus in a range that has already been determined by other groups (Herne T. M., Tarlov M. J. J. Am. Chem. Soc. 1997, 119, 8916-8920).

All the above electrochemical experiments were carried out in a three-electrode setup with the gold working electrode to be analyzed, a Pt counter electrode and a reference electrode (Ag/AgCl/3M KCl) using an Autolab 12 potentiostat (Ecochemie, Netherlands).

EXAMPLE 15

2 mmol of p-tosyl chloride is added to a solution of trans-1,2-dithiane-4,5-diol (2 mmol in anhydrous pyridine). After stirring for 2 hours at room temperature the solvent is evaporated. 0.5 eq ethylene diamine in DMF is stirred in the presence of NaH for 10 min at room temperature. Compound 10 (see FIG. 6) is dissolved in DMF and added to the ethylendiamin solution above. The reaction mixture is stirred under reflux for 6 hours. The desired product 11 (see FIG. 6) is isolated by silica gel chromatography and reacted with 1 eq DMT-Cl in pyridine obtaining product 12 (see FIG. 6). The DMT protected product is purified by silica gel chromatography (eluent: ethylacetate/n-heptane in presence of 1% Et₃N). 1 mmol of product 12 (see FIG. 6) is dissolved in 10 ml of anhydrous DCM in an argon atmosphere. The solution is cooled in an ice bath and 4 eq of N,N′-diisopropylethylamine is added dropwise while stirring. Using a syringe, 1.2 eq of chlor-(2-cyanoethoxy)(diisopropylamino)-phosphine is added dropwise. After 1.5 hours of stirring at room temperature the reaction mixture is diluted with DCM and worked up with standard methods. For purification of product 13 (see FIG. 6) silica gel chromatography is used (eluent: ethylacetate/n-heptane in presence of 1% Et₃N).

EXAMPLE 16

1 g (8 mmol) of 2,3-dimercapto-1-propanol is dissolved in ACN and oxidized by air (oxygen). The corresponding cyclic compound 14 (see FIG. 7) is reacted with MsCl (Mesylchloride) in the presence of Et₃N. After 2 hours stirring at room temperature the solvent is evaporated in a rotary evaporator. A solution of 1 eq MMT-Ethylendiamine is treated with NaH in DMF. After 30 min stirring at room temperature 1 eq of compound 14 (see FIG. 7) in DMF is added to the MMT-Ethylendiamine solution above. The reaction mixture is stirred under reflux for 4 hours. The solvent is reduced with a rotary evaporator, the residue is worked up with standard methods and purified with silica gel chromatography.

The MMT group of compound 16 (see FIG. 7) is cleaved with an acidic solution (2% DCA in DMF). 1 eq of compound 17 (see FIG. 7) is dissolved in DMF and reacted with N-α-Fmoc-N-ε-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl-L-Lysine (compound 18 (see FIG. 7)) in presence of HOBt and DCC. The reaction is carried out overnight at room temperature. The solvent is evaporated and the residue is worked up with standard methods and purified with silica gel chromatography using ethylacetate/n-heptane as eluent.

The FMOC group of compound 19 (see FIG. 7) is cleaved selectively with a solution of 500 mmol/l DBU in ACN. The free amino group of product 20 (see FIG. 7) reacts with BrCH₂CH₂COOH to obtain product 21 (see FIG. 7) as the main product. The raw material is purified with silica gel chromatography using ethylacetate/n-heptane as eluent.

EXAMPLE 17

1 eq each of compund 22 (see FIG. 8), DCC and HOBt is added to a solution of 1 g (4.7 mmol) of 1,3,5-Benzene-tricarboxylic acid in anhydrous DMF. The reaction mixture is stirred overnight at room temperature. The solvent is concentrated and the desired product 23 (see FIG. 8) is isolated with silica gel chromatography. Compound 23 (see FIG. 8) is dissolved in DMF and reacts with Fmoc-ethylendiamine in the presence of DCC and HOBt. After reducing the solvent in a vacuum, the raw product is purified with silica gel chromatography using ethylacetate/n-heptane as eluent.

EXAMPLE 18

1.2 eq of Fmoc-Cl ((9-Fluorenylmethyl)-chloroformate) are added to a solution of 2 g (13 mmol) of 3,5-Diamino benzoic acid in 40 ml anhydrous pyridine. After 2 hours stirring at room temperature the solvent is evaporated and the raw product is purified with silica gel chromatography using ethylacetate/n-heptane as eluent. Compound 25 (see FIG. 9) is dissolved in a mixture of ACN and dioxane and reacted with lipoic acid N-Hydroxy-succinimide ester. The reaction mixture is stirred overnight at room temperature. The solvent is removed with a rotary evaporator and the residue is dissloved in DCM and worked up with standard methods. The raw product is purified with silica gel chromatography using ethylacetate/n-heptane as eluent to isolate the desired product 27 (see FIG. 9). 

1. Compounds of the formula

wherein Z is a hydrocarbon comprising 2 to 28 C atoms, wherein Z may in addition comprise the elements N, O, P, S, Si and halogen, R¹ and R² are equal or different H or sulfur protecting groups, wherein both S atoms may form a disulfide bridge with R¹, R² not being present, protecting-group-Y¹ is protecting-group-NH, protecting-group-NR⁴, protecting-group-O, CONH-protecting-group, protecting-group-OOC, protecting-group-S—S, —CH(protecting-group-O)₂, or —CR⁵(protecting-group-O)₂ or protecting-group-S, Y² is —OH, —NH₂, —NHR³, —NR³R⁴, —COOH, —COCl, —COOCO—R⁶, —CONH₂, —CONHR³, —COOR³, —SO₃H, —SO₃Cl, —SH, —S—SR³, —CHO, —COR³, —C₂H₃O, halogen, —N₃, —NH—NH₂, —NCO, —NCS, wherein R³ is alkyl, heteroalkyl, aryl, cycloalkyl or a protecting group, wherein R³ comprised in the groups Y¹ and Y² may be equal or different, R⁴ is a protecting group, wherein R⁴ comprised in the groups Y¹ and Y² may be equal or different, and wherein R⁴ and R³ may be equal or different, R⁵ is alkyl, aryl, cycloalkyl, wherein R⁵ comprised in the groups Y¹ and Y² may be equal or different and R⁶ is alkyl, heteroalkyl, aryl, or cycloalkyl, wherein R⁶ comprised in the groups Y¹ and Y² may be equal or different, wherein Y² may also be a group of the formula (II) or (III),

wherein X¹ is halogen or substituted amine, X² is alkyl, alkoxy, aryloxy or a cyano derivative of alkyl, alkoxy, aryloxy, X³ is halogen, amino group or oxygen and X⁴ is alkyl, alkoxy, aryloxy or X⁴ is H if X³ is oxygen.
 2. The compounds according to claim 1 wherein Z is a hydrocarbon comprising 2 to 28 C atoms, wherein Z may also comprise the elements N, O, P and S.
 3. The compounds according to claim 2 wherein Z is a hydrocarbon comprising 2 to 28 C atoms, wherein Z may also comprise the elements N, O and P.
 4. The compounds according to claim 3 wherein Z is a hydrocarbon comprising 2 to 28 C atoms, wherein Z may also comprise the elements N and O.
 5. The compounds according to claim 4 wherein Z is a hydrocarbon comprising 2 to 28 C atoms, wherein Z may also comprise the elements N and O and wherein the elements N and O are present solely as part of an amide bond.
 6. The compounds according to claim 3 wherein Z is a hydrocarbon comprising 2 to 28 C atoms, wherein Z may also comprise the elements P and O.
 7. The compounds according to claim 6 wherein Z is a hydrocarbon comprising 2 to 28 C atoms, wherein Z may also comprise the elements P and O and wherein the elements P and O are present solely as part of a phosphor diester bond.
 8. The compounds according to one of the preceding claims wherein Z is a hydrocarbon comprising 2 to 8 C atoms.
 9. The compounds according to claim 8 wherein Z is a hydrocarbon comprising 4 C atoms and 6 H atoms.
 10. The compounds according to any of claims 1 to 8 of the formula

wherein A¹, A², A³, A⁴, A⁵, A⁶ are equal or different alkyl comprising 1-22 C atoms, heteroalkyl comprising 1-22 C atoms, cycloalkyl comprising 1-22 C atoms, H, protecting-group-Y¹ or group Y², wherein A¹, A², A³, A⁴, A⁵, A⁶ may also comprise protecting-group-Y¹ and group Y² and wherein protecting-group Y¹ as well as group Y² is present at least once.
 11. The compounds according to claim 10 wherein A² and A⁴ are protecting-group-Y¹ or Y², wherein A², A⁴ may also comprise protecting-group-Y¹ and group Y² and wherein protecting-group-Y¹ as well as group Y² are present at least once.
 12. The compounds according to claim 11 wherein A², A⁴ are protecting-group-Y¹, Y²
 13. The compounds according to any of claims 10 to 12 wherein A², A³, A⁵ and A⁶ are H.
 14. The compounds according to claim 13 wherein protecting-group-Y¹ is protecting-group-OOC, protecting-group-O, protecting-group-S, protecting-group-NH or protecting-group-NR^(y) and Y² is COOH, COOR^(x), OH, OR^(x), SH, SR^(x), NH₂, NHR^(x), NR^(x)R^(y), wherein R^(x) is a protecting group and R^(y) is alkyl comprising 1-15 C atoms, aryl comprising 1-14 C atoms, cycloalkyl comprising 1-15 C atoms, heteroalkyl comprising 1-15 C atoms, a protecting group or a group of the formula (II) or (III).
 15. The compounds according to claim 13 wherein A² is protecting-group-O, protecting-group-OOC or protecting-group-NH, wherein A⁴ is COOH, a group of the formula (II) or (III) or protecting-group-NH, and R¹=R²=DMT or both S atoms are joined together to form a disulfide bridge with R¹, R² not being present.
 16. The compounds according to any of claims 1 to 8 of the formula

wherein D¹, D², D³, D⁴, D⁵, D6 are equal or different alkyl comprising 1-22 C atoms, heteroalkyl comprising 1-22 C atoms, cycloalkyl comprising 1-22 C atoms, H, protecting-group-Y¹ or group Y², wherein D¹, D², D³, D⁴, D⁵, D⁶ may also comprise protecting-group-Y¹ and group Y² and wherein protecting-group-Y¹ as well as group Y² are present at least once.
 17. The compounds according to claim 16 wherein D² or D⁴ or D6 is protecting-group-Y¹ or Y² and D² or D⁴ or D⁶ comprise the groups protecting-group-Y¹ or Y², wherein protecting-group-Y¹ as well as group Y² are present at least once.
 18. The compounds according to claim 16 or 17 wherein D¹, D², D³ and D⁵ are H and D⁴ and D⁶ comprise protecting-group-Y¹ and group Y^(2.)
 19. The compounds according to claim 18 wherein protecting-group-Y¹ is protecting-group-OOC, protecting-group-O, protecting-group-S, protecting-group-NH or protecting-group-NR^(y) and Y² is COOH, COOR^(x), OH, OR^(x), SH, SR^(x), NH₂, NHR^(x) or NR^(x)R^(y), wherein R^(x) is a protecting group and R^(y) is alkyl comprising 1-15 C atoms, aryl comprising 1-14 C atoms, cycloalkyl comprising 1-15 C atoms, heteroalkyl comprising 1-15 C atoms, a protecting group or a group of the formula (II) or (III).
 20. The compounds according to claim 16 or 17 wherein D¹, D², D³ and D⁵ are H and D⁴ and D⁶ are protecting-group-Y¹, Y².
 21. The compounds according to claim 16 or 17 wherein D¹, D², D³, D⁴ and D⁵ are H and D6 is heteroalkyl comprising 1-22 C atoms or cycloheteroalkyl comprising 1-22 C atoms, wherein D⁶ comprises protecting-group-Y¹ and Y², wherein R¹=R²=DMT or both S atoms are joined together to form a disulfide bridge with R¹, R² not being present.
 22. The compounds according to any of claims 1 to 8 of the formula

wherein B¹, B², B³ and B⁴ are equal or different alkyl comprising 1-22 C atoms, heteroalkyl comprising 1-22 C atoms, cycloalkyl comprising 1-22 C atoms, H, protecting-group-Y¹ or group Y², wherein B¹, B², B³and B⁴ may also comprise protecting-group-Y¹ and group Y² and wherein protecting-group-Y¹ as well as group Y² are present at least once.
 23. The compounds according to claim 22 wherein B² or B⁴ is protecting-group-Y¹ or Y² and either B² or B⁴ comprise protecting-group-Y¹ or group Y², wherein protecting-group-Y¹ as well as group Y² are present at least once.
 24. The compounds according to claim 22 or 23 wherein B¹, B² and B³ are H and B⁴ comprise the groups protecting-group-Y¹ and Y².
 25. The compounds according to claim 24 wherein B⁴ is heteroalkyl comprising 1-22 C atoms or cycloheteroalkyl comprising 1-22 C atoms, wherein B⁴ comprises the groups protecting-group-Y¹ and Y², wherein protecting-group-Y¹ is protecting-group-OOC, protecting-group-O or protecting-group-NH and Y² is COOH, COOR^(x), OR^(x), NHR^(x) or a group of formula (II), wherein R^(x) is DMT or Fmoc and R¹=R²=DMT or both S atoms are joined together to form a disulfide bridge with R¹, R² not being present.
 26. The compounds according to any of the preceding claims wherein Y² is equivalent to formula II or III, wherein X¹ is halogen and X² is methyl or R⁷O—, or X² is R⁷O— and X¹ is —NR⁸R⁹, wherein R⁷ is alkyl, cycloalkyl, aryl, cyanoalkyl, cyanocycloalkyl or cyanoaryl, and wherein R⁸ and R⁹ are independently from each other alkyl, heteroalkyl, cycloalkyl, aryl or R⁸ and R⁹ are joined together to form a cyclic structure including the N atom, said cyclic structure comprising 4 to 7 C atoms, wherein one C atom of said cyclic structure may be replaced by O or S, or X³═O⁻ and X⁴═H or R¹⁰O—, wherein R¹⁰ is a protecting group.
 27. The compounds according to claim 26 wherein R⁷ is a base labile protecting group.
 28. The compounds according to claim 27 wherein R⁷ is a base labile protecting group selected from β-cyanoethyl, β-nitroethyl, 2,2,2-trichlorethyl, methyl, 1,1-dimethyl-2,2,2-thrichlorethyl, 2,2,2-tribromethyl, benzyl, o-chlorphenyl, p-nitrophenylethyl, 2-methylsulfonylethyl and 1,1-dimethyl-2-cyanoethyl.
 29. The compounds according to any of claims 26 to 28 wherein R⁸ and R⁹ are independently from each other alkyl comprising 1 to 16 C atoms, cycloalkyl comprising 3 to 8 C atoms, aryl comprising 6 to 20 C atoms, or R⁸ and R⁹ are joined together to form a cyclic structure including an N atom, said cyclic structure comprising 4 to 7 C atoms, wherein a C atom of the cyclic structure may be replaced by O or S.
 30. The compounds according to claim 29 wherein R⁸ and R⁹ are independently from each other alkyl comprising 1 to 6 C atoms.
 31. The compounds according to claim 29 wherein R⁸ and R⁹ are isopropyl, butyl, hexyl, nonyl, dodecyl, hexadecyl, cyclopropyl, cyclobutyl, cyclohexyl, cyclooctyl, phenyl, tolyl, benzyl, xylyl, naphthyl, morpholino, piperidinyl or thiomorpholino.
 32. The compounds according to claims 28 to 31 wherein protecting-group-Y¹ is protecting-group-O, protecting-group-S or protecting-group-NR⁴, and wherein the protecting group is a acid labile protecting group and R⁴ is hydrogen, alkyl, aryl or cycloalkyl.
 33. The compounds according to claim 32 wherein protecting-group-Y¹ is protecting-group-O and protecting-group is 4,4′-dimethoxytrityl, 9-fluorenylmethoxycarbonyl or 4-monomethoxtrityl.
 34. The compounds according to any of the preceding claims wherein R¹ and R² are trityl, 4,4′-dimethoxytrityl, 4-monomethoxytrityl, 9-fluorenylmethyl, 9-fluorenylmtehoxycarbonyl, 2,4-dinitrophenylethyl, 2,4,6-trimethoxybenzyl, 4-methoxybenzyl or allyloxycarbonylaminomethyl.
 35. Use of the compounds according to any of the preceding claims for the modification of oligomers.
 36. Use of the compounds according to claims 1 to 34 for the immobilization of modified oligomers on surfaces.
 37. Use of the compounds according to claims 1 to 34 for the conjugation of enzymatic, chromogene, fluorogene, radioactive or chemiluminiscent labels, substances intercalating in nucleic acids, metals, metal ions, hormones, proteins, peptides, nucleolytic and proteolytic agents, biotin, antigens, haptens, antibodies or receptors to molecules or oligomers.
 38. Use of the compounds according to claims 1 to 34 for the automatic synthesis of oligomers.
 39. Use according to any of claims 35 to 38 wherein the oligomers are oligonucleotides, polypeptides, PNA or LNA (Locked Nucleic Acid). 